Detalhe da pesquisa
1.
Phospholipid Type Regulates Protein Corona Composition and In Vivo Performance of Lipid Nanodiscs.
Mol Pharm
; 21(5): 2272-2283, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607681
2.
Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin.
Acta Pharmacol Sin
; 45(3): 646-659, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845342
3.
Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv.
Nano Lett
; 21(23): 10107-10113, 2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34812646
4.
Deciphering Protein Corona by scFv-Based Affinity Chromatography.
Nano Lett
; 21(5): 2124-2131, 2021 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617264
5.
Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
J Med Chem
; 67(9): 7330-7358, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661655
6.
Lipid-Based Nanocarriers Enabled Oral Delivery of Oleanolic Acid Derivative DKS26 for Diabetes Management.
Adv Healthc Mater
; 12(16): e2300639, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36977335
7.
Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
Expert Opin Drug Deliv
; 19(7): 833-846, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35738018
8.
Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines.
J Control Release
; 330: 493-501, 2021 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33383098